S&P Futures
3,832.25-6.75(-0.18%)Dow Futures
31,497.00+32.00(+0.10%)Nasdaq Futures
12,565.00-98.75(-0.78%)
Eli Lilly and Company (LLY)
| Previous Close | 200.54 |
| Open | 201.02 |
| Bid | 207.10 x 800 |
| Ask | 207.60 x 1800 |
| Day's Range | 200.88 - 207.67 |
| 52 Week Range | 117.06 - 218.00 |
| Volume | 3,876,160 |
| Avg. Volume | 4,318,336 |
| Market Cap | 198.318B |
| Beta (5Y Monthly) | 0.28 |
| PE Ratio (TTM) | 30.47 |
| EPS (TTM) | 6.79 |
| Earnings Date | Apr 27, 2021 |
| Forward Dividend & Yield | 3.40 (1.64%) |
| Ex-Dividend Date | Feb 11, 2021 |
| 1y Target Est | 216.14 |
- Reuters
EU regulator advises on use of Lilly's COVID-19 antibody cocktail
The recommendation can now be used as guidance in individual European nations on the possible use of the combination of bamlanivimab and etesevimab, before a broader approval is given, the European Medicines Agency (EMA) said. The medicines in the cocktail, given via a drip, belong to a class of drugs known as monoclonal antibodies, which are synthetically manufactured copies of infection-fighting proteins produced naturally by the human body. The EMA said while results indicated the combination reduced the amount of virus present in the back of the nose and throat, there was some uncertainty around the benefits of using bamlanivimab alone.
- Reuters
UPDATE 1-EU regulator advises on use of Lilly's COVID-19 antibody cocktail
Europe's medicines regulator said on Friday Eli Lilly and Co's antibody drug combination can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness. The recommendation can now be used as guidance in individual European nations on the possible use of the combination of bamlanivimab and etesevimab, before a broader approval is given, the European Medicines Agency (EMA) said. The EMA said while results indicated the combination reduced the amount of virus present in the back of the nose and throat, there was some uncertainty around the benefits of using bamlanivimab alone.
- PR Newswire
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The CHMP scientific opinion under Article 5.3 of regulation 726/2004 provides a harmonized, EU-level opinion on the efficacy, quality, and safety of the antibodies. The opinion can now be considered by the EU member states when making decisions on the use of the therapies at a national level before a formal marketing authorization is issued.
